~ Buy the MYOVIEW 30ML (technetium tc-99m tetrofosmin kit) Drug Profile, 2024 PDF Report in the Report Store ~

MYOVIEW 30ML Drug Patent Profile

✉ Email this page to a colleague

When do Myoview 30ml patents expire, and what generic alternatives are available?

Myoview 30ml is a drug marketed by Medi-physics and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

DrugPatentWatch^® Generic Entry Outlook for Myoview 30ml

Myoview 30ml was eligible for patent challenges on February 9, 2000.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for MYOVIEW 30ML?
What are the global sales for MYOVIEW 30ML?
What is Average Wholesale Price for MYOVIEW 30ML?

Summary for MYOVIEW 30ML

International Patents:	8
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
DailyMed Link:	MYOVIEW 30ML at DailyMed

Drug patent expirations by year for MYOVIEW 30ML

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MYOVIEW 30ML

Generic Entry Date for MYOVIEW 30ML^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 020372 Dosage: INJECTABLE;INJECTION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MYOVIEW 30ML

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Pharma Inc	Phase 2
GE Healthcare	Phase 4

See all MYOVIEW 30ML clinical trials

US Patents and Regulatory Information for MYOVIEW 30ML

MYOVIEW 30ML is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of MYOVIEW 30ML is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting MYOVIEW 30ML

Radiopharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-002	Jul 7, 2005		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for MYOVIEW 30ML

When does loss-of-exclusivity occur for MYOVIEW 30ML?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Patent: 1861170
Patent: Improved radiopharmaceutical composition
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 90484
Patent: COMPOSITION RADIOPHARMACEUTIQUE AMÉLIORÉE (IMPROVED RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Hong Kong

Patent: 49203
Patent: IMPROVED RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 64328
Estimated Expiration: ⤷ Sign Up

Patent: 10539222
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 62441
Estimated Expiration: ⤷ Sign Up

United Kingdom

Patent: 18386
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MYOVIEW 30ML around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Denmark	163289		⤷ Sign Up
China	101861170	Improved radiopharmaceutical composition	⤷ Sign Up
Taiwan	206231		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for MYOVIEW 30ML

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands	⤷ Sign Up	PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description